vimarsana.com
Home
Live Updates
Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release : vimarsana.com
Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral...
Related Keywords
Italy ,
Milan ,
Lombardia ,
United States ,
Spain ,
Barcelona ,
Comunidad Autonoma De Cataluna ,
Rosalia Scampoli ,
Katie Mcmanus ,
Toby Maher ,
Venereology Congress ,
European Academy Of Dermatology ,
Prnewswire Trevi Therapeutics Inc ,
European Respiratory Society International Congress ,
University Of Southern California ,
Nasdaq ,
Exchange Commission ,
University Hospital ,
International Congress ,
European Respiratory Society ,
Trevi Therapeutics Inc ,
European Academy ,
Interstitial Lung Disease ,
Keck School ,
Late Breaking ,
Nalbuphine Extended Release Is Effective ,
Severe Prurigo Nodularis ,
Associated Pruritus ,
Results From ,
Worst Itch Numerical Rating Scale ,
Prurigo Activity Score ,
Chronic Cough ,
Idiopathic Pulmonary ,
Trevi Therapeutics ,
New Haven ,
Fast Track ,
Private Securities Litigation Reform Act ,
Nc ,
vimarsana.com © 2020. All Rights Reserved.